Antioxidant vitamins C and E supplementation increases markers of haemolysis in sickle cell anaemia patients: a randomized, double-blind, placebo-controlled trial

Autor(es)

Arruda, Martha M. ^[1] ; Mecabo, Grazielle ^[1] ; Rodrigues, Celso A. ^[1] ; Matsuda, Sandra S. ^[1] ; Rabelo, Iara B. ^[1] ; Figueiredo, Maria S. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Fed Sao Paulo, UNIFESP, Hematol & Blood Transfus Dept, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: British Journal of Haematology; v. 160, n. 5, p. 688-700, MAR 2013.
• Citações Web of Science: 12

Resumo

Erythrocytes from sickle cell anaemia (SCA) patients continuously produce larger amounts of pro-oxidants than normal cells. Oxidative stress seems to primarily affect the membrane and results in haemolysis. The use of antioxidants in vitro reduces the generation of pro-oxidants. To evaluate the impact of vitamins C (VitC) and E (VitE) supplementation in SCA patients, patients over 18years were randomly assigned to receive VitC 1400mg+VitE 800mg per day or placebo orally for 180d. Eighty-three patients were enrolled (44 vitamins, 39 placebo), median age 27 (1868) years, 64% female. There were no significant differences between the two groups regarding clinical complications or baseline laboratorial tests. Sixty percent of the patients were VitC deficient, 70% were VitE deficient. Supplementation significantly increased serum VitC and E. However, no significant changes in haemoglobin levels were observed, and, unexpectedly, there was a significant increase in haemolytic markers with vitamin supplementation. In conclusion, VitC+VitE supplementation did not improve anaemia and, surprisingly, increased markers of haemolysis in patients with SCA and S-0-thalassaemia. The exact mechanisms to explain this findings and their clinical significance remain to be determined. (AU)

• Processo FAPESP: 10/02933-6 - Avaliação da ação dos antioxidantes Vitamina C e E no perfil hemolítico de pacientes com doença falciforme: estudo prospectivo, randomizado, duplo-cego, placebo-controlado
• Beneficiário: Maria Stella Figueiredo
• Modalidade de apoio: Auxílio à Pesquisa - Regular